v3.26.1
FAIR VALUE - Narrative (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Sep. 16, 2024
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2023
USD ($)
Nov. 19, 2021
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Money market fund   $ 269,466,000   $ 269,466,000   $ 209,891,000    
Interest rate swap   1,124,000   1,124,000   1,646,000    
Unrealized gain (loss) on investment in equity securities   741,000 $ 332,000 6,494,000 $ (589,000)      
Securities held, value   15,626,000   $ 15,626,000   9,131,000 $ 0  
Achievement of milestones payment period       24 months        
Contingent consideration / contingent value rights   $ 8,500,000   $ 8,500,000   8,300,000    
CG Oncology                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Shares held (in shares) | shares   219,925   219,925        
Investment, cost   $ 71.05   $ 71.05   41.52    
Accrued Licensor Payments                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Fair value of payments       15,600,000   9,100,000    
Alimera Sciences, Inc | Contingent Value Rights Agreement                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Contingent consideration classified as equity, fair value disclosure   500,000   500,000   1,400,000    
Increase (decrease) in fair value disclosure       (900,000)        
Alimera Sciences, Inc                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Business combination, milestone payment multiplier 0.25              
Contingent consideration / contingent value rights   518,000   518,000   1,428,000    
Novitium                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Additional contingent consideration   46,500,000   $ 46,500,000        
Net profit generated by the sales       20.00%        
Maximum net profit generated by sales owed   21,500,000   $ 21,500,000        
Payment period       45 days        
Collaborative arrangement, percentage of net profit generated by sales, quarterly payment due, accrued   100,000 $ 100,000 $ 100,000 $ 100,000      
Novitium                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Contingent consideration / contingent value rights   $ 8,455,000   $ 8,455,000   $ 8,348,000   $ 30,800,000
2026 Milestone Revenue Payment | Alimera Sciences, Inc                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Revenues $ 140,000,000.0              
Business combination, divisible revenue $ 10,000,000.0              
2027 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Contingent consideration, milestone payment, CVRs agreement business days 15 days              
2027 Milestone Revenue Payment | Alimera Sciences, Inc                
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                
Revenues $ 160,000,000.0              
Business combination, divisible revenue $ 15,000,000.0